(E)-4-{2-[[3-(Indol-5-yl)-1-oxo-2-butenyl]amino]phenoxy}butyric Acid Derivatives: A New Class of Steroid 5.alpha.-Reductase Inhibitors in the Rat Prostate. 1

1995 ◽  
Vol 38 (15) ◽  
pp. 2887-2892 ◽  
Author(s):  
Toshiaki Kumazawa ◽  
Hitoshi Takami ◽  
Nobuyuki Kishibayashi ◽  
Akio Ishii ◽  
Yoshitomo Nagahara ◽  
...  
Keyword(s):  
Butyric Acid ◽  
New Class ◽  
Reductase Inhibitors ◽  
Rat Prostate ◽  
5 Alpha Reductase Inhibitors

ChemInform Abstract: (E)-4-(2-((3-(Indol-5-yl)-1-oxo-2-butenyl)amino)phenoxy)butyric Acid Derivatives: A New Class of Steroid 5α-Reductase Inhibitors in the Rat Prostate. Part 1.

ChemInform ◽  
2010 ◽  
Vol 26 (47) ◽  
pp. no-no
Author(s):  
T. KUMAZAWA ◽  
H. TAKAMI ◽  
N. KISHIBAYASHI ◽  
A. ISHII ◽  
Y. NAGAHARA ◽  
...  
Keyword(s):  
Butyric Acid ◽  
New Class ◽  
Reductase Inhibitors ◽  
Rat Prostate

Steroidal A ring aryl carboxylic acids: a new class of steroid 5.alpha.-reductase inhibitors

1990 ◽  
Vol 33 (3) ◽  
pp. 937-942 ◽  
Author(s):  
Dennis A. Holt ◽  
Mark A. Levy ◽  
David L. Ladd ◽  
Hye Ja Oh ◽  
Jill M. Erb ◽  
...  
Keyword(s):  
Carboxylic Acids ◽  
New Class ◽  
Reductase Inhibitors ◽  
5 Alpha Reductase Inhibitors

scholarly journals Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

Uro ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 82-98
Author(s):  
Antonio La Torre ◽  
Caterina Palleria ◽  
Irene Tamanini ◽  
Andrea Scardigli ◽  
Tommaso Cai ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Sexual Dysfunction ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Sexual Dysfunctions ◽  
Reductase Inhibitors ◽  
Urinary Tract Symptoms ◽  
5 Alpha Reductase Inhibitors ◽  
Lower Urinary

This is a critical review of the current literature data about sexual dysfunction as a potential side effect related to drugs commonly used for the treatment of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. In this narrative review, we analyzed data from the literature related to the development of sexual dysfunctions during the treatment of BPH or LUTS. Both α-blockers and 5-alpha reductase inhibitors (5-ARIs) can induce erectile dysfunction, ejaculatory disorders and a reduction in sexual desire. The sexual side effect profile of these drugs is different. Among the α-blockers, silodosin appears to have the highest incidence of ejaculatory disorders. Persistent sexual side effects after the discontinuation of finasteride have been recently reported; however, further studies are needed to clarify the true incidence and the significance of this finding. However, most of the published studies are affected by a weak methodology and other important limitations, with only a few RCTs available. Therefore, it is desirable that future studies will include validated tools to assess and diagnose the sexual dysfunction induced by these medications, especially for ejaculation and sexual desire disorders.

scholarly journals 4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor.

1984 ◽  
Vol 259 (2) ◽  
pp. 734-739
Author(s):  
T Liang ◽  
C E Heiss ◽  
A H Cheung ◽  
G F Reynolds ◽  
G H Rasmusson
Keyword(s):  
Androgen Receptor ◽  
Reductase Inhibitors ◽  
5 Alpha Reductase Inhibitors

Effects of Topical Antiandrogen and 5-Alpha-Reductase Inhibitors on Sebaceous Glands in Male Fuzzy Rats

1997 ◽  
Vol 10 (5-6) ◽  
pp. 288-297 ◽  
Author(s):  
Fangfang Ye ◽  
Koji Imamura ◽  
Noriko Imanishi ◽  
Linda Rhodes ◽  
Hideo Uno
Keyword(s):  
Sebaceous Glands ◽  
Reductase Inhibitors ◽  
5 Alpha Reductase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document